A61K 40/4268
Mage
Official title: {mage}
A61K40/4268 (Mage) appears on 140 US grants and 283 published applications in this corpus.
Search patents in A61K- Granted patents
- 140
- Published applications
- 283
- Assignees
- 122
- Inventors
- 485
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 0 |
| 2002 | 2 | 1 |
| 2003 | 2 | 7 |
| 2004 | 5 | 8 |
| 2005 | 0 | 4 |
| 2006 | 2 | 6 |
| 2007 | 2 | 1 |
| 2008 | 1 | 7 |
| 2009 | 1 | 5 |
| 2010 | 5 | 6 |
| 2011 | 5 | 5 |
| 2012 | 4 | 9 |
| 2013 | 5 | 5 |
| 2014 | 3 | 9 |
| 2015 | 5 | 5 |
| 2016 | 5 | 6 |
| 2017 | 3 | 16 |
| 2018 | 6 | 7 |
| 2019 | 2 | 16 |
| 2020 | 8 | 10 |
| 2021 | 7 | 11 |
| 2022 | 9 | 37 |
| 2023 | 11 | 25 |
| 2024 | 12 | 38 |
| 2025 | 13 | 20 |
| 2026 | 14 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method of treatment of cancer or tumour29 Sep 2026US 12,746,272 B2
- Engineered T cell receptors and methods of use22 Sep 2026US 12,742,002 B2Board of Regents, The University of Texas System
- Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer22 Sep 2026US 12,742,153 B2Children's National Medical Center
- Cell/gene therapies targeting MAGE-A4 peptide21 Jul 2026US 12,685,774 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Compositions and methods of enhancing immunotherapies9 Jun 2026US 12,648,927 B2Cha Therapeutics, Inc.
- Plasmacytoid dendritic cells for treating cancer17 Sep 2026US 2026/0272977 A1Pdc Line Pharma
- High-affinity tcr for identifying mage-a4 antigen, and sequence and use thereof10 Sep 2026US 2026/0265336 A1Xlifesc, Ltd.
- Plasmacytoid dendritic cells and immune checkpoint inhibitor for cancer treatment13 Aug 2026US 2026/0232798 A1Pdc Line Pharma
- Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof13 Aug 2026US 2026/0232804 A1TScan Therapeutics, Inc.
- Anti-mage-a4 t cell receptors6 Aug 2026US 2026/0226134 A1Zelluna Immunotherapy AS
Most cited
By later US patents
- Methods of enhancing T cell responsiveness132US 7,794,710 B2Mayo Foundation for Medical Education and Research · 2010
- Compositions and methods for identifying antigens which elicit an immune response89US 6,500,641 B1Wake Forest University School of Medicine · 2002
- Antigenic polypeptide usable as therapeutic agent for malignant neoplasm76US 8,323,657 B2National University Corporation Hokkaido University · 2012
- HLA class I A2 tumor associated antigen peptides and vaccine compositions58US 6,602,510 B1Epimmune Inc. · 2003
- Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of CTL49US 5,846,827 ACytel Corporation · 1998